HHS Affordability Czar Says Healthcare Costs Stem From Incentives, Not Coverage

Healthcare affordability czar Casey Mulligan laid out the economic philosophy guiding the Trump administration’s approach to healthcare costs during a recent conference address. He argued that provider taxes and state-directed payments inflate healthcare spending far beyond Medicaid and ultimately raise costs for employers and taxpayers. The post HHS Affordability Czar Says Healthcare Costs Stem From…

Read More

Incyte’s $1.25B Buyout Brings What Could Become the Next Big Bleeding Disorder Drug

Incyte’s Vega Therapeutics acquisition comes with a late-stage drug offering a novel mechanism of action and a dosing advantage compared to currently available therapies for von Willebrand disease, an inherited bleeding disorder. The deal comes as patent expiration looms for Jakafi, currently Incyte’s top product. The post Incyte’s $1.25B Buyout Brings What Could Become the…

Read More